The U.S. obesity epidemic accounts for more than $1.7 trillion in annual costs, with $480 billion in direct medical expenses and another $1.24 trillion in indirect costs. Payers are increasingly responsible for managing the rising cost of GLP-1 medications, but without a targeted prescribing framework, spending is often misaligned with outcomes. This leads to avoidable costs, coverage inefficiencies, and inconsistent patient results.
